TuHURA Biosciences Inc

With the transition into Stage 3 distribution and the long-term downtrend intact, HURA’s medium-term bias is bearish. Price has failed to clear the flattened 9/21 EMAs and was rejected at this resistance zone on elevated volume. Short-term execution favors immediate sell-side participation on this clear rejection. Under a speculative framework, clear structural asymmetry justifies a Sell Now posture, with the downtrend confirmed unless HURA can reclaim key moving average levels.

• ↑MDSC inhibitor program advancing into in vivo AML trials in late 2026.
• ↑R&D expenses rose 34% to $6.6M, underscoring focus on clinical innovation.
• ↓Q2 net loss $9.2M on zero revenue raises cash-burn concerns.